The Orphan Drug Tax Credit as a Strategic Asset 

Standalone Value, Transactional Survivability, and Diligence Readiness under IRC § 45C 

The orphan drug tax credit is routinely undervalued by the companies best positioned to use it, because its worth is judged through a single, pessimistic question: will it survive a sale? That question captures only one of the credit’s three forms of value, and the least favorable one. This manuscript sets out the case that the credit under § 45C of the Internal Revenue Code is better understood as a three-dimensional asset, standalone, transactional, and diligence-related, each governed by different mechanics and each worth assessing on its own terms. 

Introduction 

Congress enacted the orphan drug incentives in 1983 to correct a structural failure in pharmaceutical markets: treatments for diseases affecting small populations rarely generate revenue sufficient to justify their development cost.¹ Among these incentives, the credit for clinical testing expenses under § 45C remains one of the most economically significant, yet also among the most inconsistently captured. The reduction of the credit rate from 50 percent to 25 percent by the 2017 tax legislation² sharpened rather than resolved the practical question: for a company in the orphan drug space, is disciplined use of the credit worthwhile, and on what basis should its value be justified? 

The prevailing intuition treats the credit chiefly as a bargaining chip in an eventual sale, then discounts it heavily because acquisition-driven ownership changes limit its post-closing use. That framing is incomplete. The credit carries three separable forms of value that respond to different legal mechanics and should be evaluated independently. Conflating them produces two symmetric errors: overstating the credit by assuming clean transferability, and dismissing it because transfer is impaired. 

The Statutory Architecture of § 45C 

The credit is not freestanding. It is computed as 25 percent of a taxpayer’s qualified clinical testing expenses (“QCTEs”) for the year and then folded into the general business credit under § 38.³ This characterization is the root of nearly every downstream consequence. Because most rare-disease developers are pre-revenue during the clinical period, they lack current tax liability to absorb the credit in the year earned. The unused amount becomes a general business credit carryforward under § 39, available for a one-year carryback and a twenty-year carryforward.⁴ What a developer accumulates, then, is a time-limited § 38/§ 39 attribute and it is the fate of that attribute, not of a discrete “orphan credit,” that governs both standalone use and transferability. 

Standalone Value: The Base Case, Not the Exception 

The most consequential observation here is also the most easily overlooked: the ownership-change limitations that dominate discussion of the credit are irrelevant to its principal use case. Those limitations are triggered only when control changes hands. A developer that advances its program to profitability applies its accumulated carryforward directly against its own liability, at full value, with no § 382 or § 383 haircut whatsoever. The impaired, transaction-driven outcome is the downside branch; full-value standalone use is the base case for any program that succeeds on its own. 

A second point elevates the standalone case from “available” to “preferred.” Because QCTEs frequently overlap with qualified research expenses, a taxpayer generally cannot claim both the § 45C credit and the § 41 research credit on the same dollars; the statute requires a choice.⁵ For qualifying orphan drug tax credit work, the § 45C election is usually the richer one. It applies a 25 percent rate to qualified spend, recognizes 100 percent of qualifying contract-research costs rather than the 65 percent allowed under § 41, and carries no incremental base-amount hurdle. A § 280C-style reduced-credit election is also available to avoid an add-back to income.⁶ Framing the decision as “whether to leverage the credit” therefore understates the stakes: the realistic alternative is not zero, but a less valuable credit taken on the identical expenditure. 

Transactional Value: Survivability Through M&A

What actually transfers 

Because the credit lives inside the § 38/§ 39 framework, an acquirer inherits, or fails to inherit, the general business credit carryforward attributable to § 45C, not a discrete orphan asset. Two legal routes place that attribute in the buyer’s hands, and a separate limitation regime then determines how much of it is usable. 

Route one: statutory succession under § 381 

In a qualifying acquisitive reorganization or a subsidiary liquidation, the target’s corporate existence ends and the acquirer succeeds to its enumerated tax attributes, including business credit carryforwards, by operation of § 381.⁷ The type F reorganization, a mere change in identity, form, or place of organization, warrants separate mention because it does not, of itself, produce an ownership change, making it the cleanest structure for attribute preservation. 

Route two: entity survival 

Where the target corporation continues to exist, no succession statute is needed: the carryforward simply remains with the surviving entity. This describes a taxable stock purchase without a § 338 election, a type B (stock-for-stock) reorganization, and most importantly for this sector, the reverse triangular merger under § 368(a)(2)(E), in which the acquirer’s merger subsidiary merges into the target and the target survives as a wholly owned subsidiary.⁸ The reverse triangular merger is the dominant structure for whole-company acquisitions of rare-disease developers, and it is therefore the structure through which inheritance most commonly arises. 

The limitation overlay 

Survival of the attribute is not the same as usability of the attribute. An acquisition ordinarily shifts more than 50 percentage points of ownership among 5-percent holders, producing an “ownership change” under § 382. Section 383 then applies an analogous limitation to pre-change credit carryforwards, capping their annual use at the tax attributable to the § 382 limitation amount, approximately the equity value of the loss corporation multiplied by the long-term tax-exempt rate, after higher-priority attributes are absorbed.⁹ Two further provisions shape the result. Under the continuity-of-business-enterprise requirement, failure to continue the target’s historic business for the requisite period can reduce the § 382 limitation to zero¹⁰; and § 384 independently restricts using acquired credits against the other party’s recognized built-in gains. For targets entering a consolidated group, separate-return-limitation-year (“SRLY”) rules impose a further, coordinated cap tied to the target’s own contribution to consolidated liability. 

Structures that defeat inheritance 

Two common structures strand the credit with the seller. A taxable asset acquisition leaves the carryforward with the selling corporation, and a stock purchase accompanied by a § 338 (or § 338(h)(10)) election recasts the transaction as a deemed asset sale, forfeiting the historic attribute at the selling level in exchange for a stepped-up asset basis.¹¹ 

The acquirer-appetite paradox 

A counterintuitive point deserves emphasis because it is routinely misjudged. When a large, profitable pharmaceutical company acquires a developer, observers assume the buyer’s ample tax appetite will finally unlock the trapped credits. It does not enlarge them. The § 382 limitation is sized off the target’s equity value, not the acquirer’s income; a profitable buyer can absorb pre-change credits only up to that target-derived annual cap. Acquirer profitability affects whether the limited amount is used, not how large the limit is. 

The Due Diligence Dimension 

The diligence value of the credit is analytically distinct from its transfer value, and it survives even a near-total § 383 haircut. A buyer’s tax attribute study proceeds far more efficiently when the target has captured the credit methodically: contemporaneous QCTE documentation, a coherent and consistent § 45C-versus-§ 41 election history, and defensible positions on the scope and timing of clinical testing. The credit has attracted administrative scrutiny and litigation over precisely these questions¹², so the difference between a clean carryforward and a speculative one is often the difference between a priced asset and a contingency. 

The consequences of poor substantiation are concrete. Aggressive or undocumented positions create diligence friction, invite purchase-price adjustments or indemnity holdbacks, and force the buyer to underwrite the attribute conservatively or disregard it. A well-documented carryforward, even one the buyer expects § 383 to throttle, is worth more than a messy one and removes an item that would otherwise slow the transaction. The discipline of consistent capture pays a return that is independent of whether the credit is ultimately transferred at all. 

An Option-Value Framing 

The three dimensions resolve into a single recommendation. Not claiming the credit forfeits the attribute entirely and permanently; claiming it preserves a valuable option at a relatively low marginal cost of substantiation. The upside branch standalone profitability delivers full value with no ownership-change limitation. The downside branch acquisition delivers impaired but frequently non-zero value in the very structures that dominate the sector, and delivers diligence value regardless. This asymmetry favors consistent capture for essentially any participant in the orphan drug space. 

The recommendation carries two disciplines. First, the value should be justified primarily on standalone optionality, the favorable election relative to § 41, and diligence readiness with transfer value modeled conservatively rather than assumed. Second, capture must be rigorous rather than aggressive: § 45C substantiation is real work, the coordination election has multi-year effects on § 41 base-period computations, and both are decisions to make deliberately with qualified counsel. A developer genuinely certain of never reaching standalone profitability and of a near-total exit haircut faces a smaller, but still generally positive, net benefit, and such certainty is rarely available in advance. 

Conclusion 

The orphan drug tax credit is poorly served by the question most often asked of it will it survive a sale?

That question captures only one of its three values, and the least favorable one. Assessed properly, the credit is a standalone asset of full value in the success case, a contingent but genuine asset in the acquisition case, and a diligence asset in every case.

For a company in the rare-disease space, the advisable posture is therefore not episodic but consistent: capture the orphan drug tax credit rigorously every year, document it as though a buyer will examine it, and let its standalone and diligence value not its uncertain transferability, carry the justification.

Footnotes

• ¹ Orphan Drug Act of 1983, Pub. L. No. 97-414. A “rare disease or condition” is generally one affecting fewer than 200,000 persons in the United States at the time of the designation request. 
• ² Tax Cuts and Jobs Act, Pub. L. No. 115-97 (2017), reducing the § 45C rate from 50% to 25% of qualified clinical testing expenses for tax years beginning after 2017. 
• ³ I.R.C. § 45C(a); I.R.C. § 38(b). QCTEs broadly track qualified research expenses under § 41, substituting “clinical testing” for “qualified research,” and are claimed on Form 8820. 
• ⁴ I.R.C. § 39(a). The credit is nonrefundable; unused amounts expire at the end of the carryforward period. 
• ⁵ I.R.C. § 45C(c) (coordination with § 41). Expenses taken into account for the § 45C credit are excluded from qualified research expenses for the § 41 credit in the same year, with further effects on § 41 base-period computations. 
• ⁶ I.R.C. § 45C(d)(3) (reduced credit election analogous to § 280C(c)(3)). By contrast, the § 41 credit is computed only on qualified spending in excess of a base amount, materially lowering its effective yield per qualified dollar. 
• ⁷ I.R.C. § 381(a), (c). Qualifying transactions include § 368(a)(1) reorganizations of types A (statutory merger), C (stock-for-assets), acquisitive D, F (mere change in form), and G (bankruptcy), as well as § 332 liquidations of an 80%-owned subsidiary. 
• ⁸ I.R.C. § 368(a)(2)(E). The structure is favored in life-sciences M&A precisely because entity survival preserves entity-held FDA orphan designations, INDs, and other regulatory approvals that would otherwise require reassignment. 
• ⁹ I.R.C. §§ 382–383. Statutory ordering generally causes net operating losses to consume the limited capacity ahead of credits; rare-disease targets typically carry substantial NOLs, which can crowd credits out of the available room. 
• ¹⁰ I.R.C. § 382(c). In practice this rarely binds in orphan-drug deals, because the acquirer generally intends to advance the very program it purchased and thereby satisfies continuity. 
• ¹¹ I.R.C. § 338. Single-asset acquisitions and in-licensing arrangements—also prevalent in the orphan drug space—do not transfer the historic carryforward at all, though the acquirer may generate its own § 45C credits on post-closing qualified expenditures if it holds the designation and continues clinical testing. 
• ¹² Disputes have centered on what constitutes qualifying clinical testing and on the eligible period, including the treatment of post-approval studies. The value lies in defensible, well-substantiated positions rather than aggressive ones. 

Sources and Authorities 

• Orphan Drug Act of 1983, Pub. L. No. 97-414, 96 Stat. 2049. 
• Tax Cuts and Jobs Act, Pub. L. No. 115-97 (2017) (reducing the § 45C credit rate to 25%). 
• I.R.C. § 45C – Clinical testing expenses for certain drugs for rare diseases or conditions. 
• I.R.C. § 38 – General business credit; I.R.C. § 39 – Carryback and carryforward of unused credits. 
• I.R.C. § 41 – Credit for increasing research activities (coordination under § 45C(c)). 
• I.R.C. § 280C – Certain expenses for which credits are allowable (reduced-credit election). 
• I.R.C. § 381 – Carryovers in certain corporate acquisitions; § 332 – Liquidations of subsidiaries. 
• I.R.C. § 382 – Limitation on NOL carryforwards after ownership change; § 383 – Special limitations on credits and capital losses. 
• I.R.C. § 384 – Limitation on use of preacquisition losses to offset built-in gains. 
• I.R.C. § 338 – Certain stock purchases treated as asset acquisitions; § 368(a)(1), (a)(2)(E) – Reorganization definitions. 
• Treas. Reg. § 1.28-1 (predecessor to § 45C). 
• Internal Revenue Service, About Form 8820, Orphan Drug Tax Credit.